- Title: Subtitle
- Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
- Creators
- Michael H. Tomasson - University of IowaShinsuke Iida - Nagoya City UniversityRuben Niesvizky - NewYork–Presbyterian HospitalMohamad Mohty - Hôpital Saint-AntoineNizar J. Bahlis - University of CalgaryJoaquin Martinez-Lopez - Hospital Universitario 12 De OctubreGuenther Koehne - Miami Transplant InstitutePaula Rodriguez-Otero - Clinica Universidad de NavarraH. Miles Prince - University of MelbourneAndrea Viqueira - PfizerEric Leip - PfizerUmberto Conte - PfizerSharon T. Sullivan - PfizerAlexander M. Lesokhin - Memorial Sloan Kettering Cancer Center
- Resource Type
- Letter/Communication
- Publication Details
- HemaSphere, Vol.8(7), pp.e136-n/a
- Publisher
- WILEY
- DOI
- 10.1002/hem3.136
- PMID
- 39055646
- PMCID
- PMC11269363
- ISSN
- 2572-9241
- eISSN
- 2572-9241
- Number of pages
- 3
- Grant note
- Pfizer Inc.
- Language
- English
- Date published
- 07/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health and Human Physiology; Internal Medicine
- Record Identifier
- 9984689159502771
Letter/Communication
Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
HemaSphere, Vol.8(7), pp.e136-n/a
07/2024
DOI: 10.1002/hem3.136
PMCID: PMC11269363
PMID: 39055646
Details
Metrics
6 Record Views